



Solution equilibrium studies on anticancer ruthenium(II)– η^6 -*p*-cymene complexes of 3-hydroxy-2(1*H*)-pyridones

Éva A. Enyedy^{a,**}, Gabriella M. Bognár^a, Tamás Kiss^{a,b,**}, Muhammad Hanif^{c,d}, Christian G. Hartinger^{c,e,*}

^aDepartment of Inorganic and Analytical Chemistry, University of Szeged, Dóm tér 7, H-6720 Szeged, Hungary

^bBioinorganic Chemistry Research Group of the Hungarian Academy of Sciences, University of Szeged, Dóm tér 7, H-6720 Szeged, Hungary

^cInstitute of Inorganic Chemistry, University of Vienna, Waehringer Str. 42, A-1090 Vienna, Austria

^dDepartment of Chemistry, COMSATS Institute of Information Technology, University Road, Abbottabad-22060, Pakistan

^eThe University of Auckland, School of Chemical Sciences, Private Bag 92019, Auckland 1142, New Zealand

ARTICLE INFO

Article history:

Received 27 September 2012

Received in revised form

25 October 2012

Accepted 25 October 2012

Keywords:

Solution equilibria

Stability constants

Chelators

Anticancer agents

Hydroxypyridones

ABSTRACT

$\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})$ complexes of bidentate (*O,O*) alkoxycarbonylmethyl-3-hydroxy-2(1*H*)-pyridone ligands exhibit *in vitro* antitumor activity. We determined the stoichiometry and stability in aqueous solution of two examples by pH-potentiometry, ¹H NMR spectroscopy and UV–vis spectrophotometry and also characterized the proton dissociation processes of the ligands. Formation of mono-ligand complexes with moderate stability was found to predominate in the physiological pH range. Moreover, the chlorido/aqua co-ligand exchange processes of the $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})(\text{H}_2\text{O})]^+$ species were also monitored and 55–65% of the aqua ligand was found to be replaced by chloride in 0.2 M KCl-containing aqueous solutions. Under basic conditions, the complexes decompose to dinuclear trihydroxido-bridged $[\text{Ru}_2(\eta^6\text{-}p\text{-cymene})_2(\text{OH})_3]^+$ and metal-free ligand and also a hydroxido species $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})(\text{OH})]$ was found. Furthermore, the ligands contain an ester functional group, which may hydrolyze at basic pH, which is however negligible at acidic or neutral pH.

© 2012 Elsevier B.V. All rights reserved.

1. Introduction

Anticancer metallodrug research started with the discovery of cisplatin and its introduction to clinical practice almost four decades ago [1,2]. The main goal of the development of novel anticancer metal-based compounds is to increase their selectivity and therapeutic index and thereby overcome the adverse effects and resistance phenomena, which are a major limitation for the curative treatment of cancer. Ruthenium compounds are currently considered as the most promising candidates for the next generation of antitumor metal complexes [2–4]. Two representatives of this class of compounds have entered clinical trials so far, *i.e.*, imidazolium trans-[tetrachlorido(dimethylsulfoxide)(1*H*-imidazole)-

ruthenate(III)] (NAMI-A) [5,6] and indazolium trans-[tetrachloridobis(1*H*-indazole)ruthenate(III)] (KP1019) [7,8]. The reduction of Ru^{III} complexes to Ru^{II} in the more reductive tumor environment as compared to normal tissue is an important step of activation. In addition to Ru^{III} coordination compounds, organometallic Ru^{II} complexes often with piano stool structure were developed and tested *in vitro* and *in vivo*. Among the $\text{Ru}^{\text{II}}(\text{arene})$ complexes a large number of $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{XY})\text{Cl}]$ -type compounds were prepared, where XY is an (*O,O*), (*O,S*), (*O,N*), (*N,N*) or (*N,S*) bidentate ligand [9–16]. The replacement of chlorido by aqua ligands can take place in aqueous solution, which is considered an essential step of activation [15,17–19]. However, the ultimate target of these organometallic $\text{Ru}^{\text{II}}(\text{arene})$ complexes is still not clear [20,21]. As other anticancer metallodrugs, they can be regarded as prodrugs and it is a prerequisite to follow their speciation in biological fluids for a better understanding of the pharmacokinetic properties and the mechanism of action. Aqueous solution equilibrium studies are a first approach to characterize possible dissociation reactions of such metal complexes in solution at low concentration. The displacement of original ligands by endogenous biomolecules strongly depends on the thermodynamic stability and kinetic inertness/lability. However, little is known about the stability of $\text{Ru}^{\text{II}}(\text{arene})$ complexes. Buglyó and co-workers

Abbreviations: CT, charge transfer; *D*, distribution coefficient; **EHP**, *N*-[(ethoxycarbonyl)methyl]-3-hydroxy-2-(1*H*)-pyridone; **EHMP**, *N*-[(ethoxycarbonyl)methyl]-3-hydroxy-4-methyl-2-(1*H*)-pyridone; MH2P, 3-hydroxy-1-methylpyrid-2(1*H*)-one; *P*, partition coefficient.

* Corresponding author. Institute of Inorganic Chemistry, University of Vienna, Waehringer Str. 42, A-1090 Vienna, Austria. Tel.: +64 9 373 7599x83220.

** Corresponding authors. Department of Inorganic and Analytical Chemistry, University of Szeged, Dóm tér 7, H-6720 Szeged, Hungary. Fax: +36 62 420505.

E-mail addresses: enyedy@chem.u-szeged.hu (É.A. Enyedy), tkiss@chem.u-szeged.hu (T. Kiss), c.hartinger@auckland.ac.nz (C.G. Hartinger).

determined stability data for $\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})$ complexes with bidentate (O,O) ligands [22,23], and also the pK_a values of the coordinated water molecule in $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{XY})(\text{H}_2\text{O})]$ species were reported [9,18,23,24]. Complexes bearing (O,O) bound hydroxypyrones show only moderate cytotoxicity and much lower stability as compared to (O,N) or (O,S) type complexes [25,26]. Switching from hydroxypyrones (such as the well-known maltol) to hydroxypyridones allows tuning the chelating ability and drug-like parameters, such as lipophilicity [18]. The Ru complex $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{EHP})\text{Cl}]$ {EHP = *N*-[(ethoxycarbonyl)methyl]-3-hydroxy-2-(1*H*)-pyridone} was previously prepared and evaluated as an anticancer agent in CH1 adenocarcinoma human cells of the ovary, showing moderate cytotoxicity (IC_{50} 240 μM) [18].

In this work, the behavior of $\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})$ complexes of the alkoxy carbonylmethyl-3-hydroxy-2(1*H*)-pyridone ligands, i.e., EHP and *N*-[(ethoxycarbonyl)methyl]-3-hydroxy-4-methyl-2-(1*H*)-pyridone (EHMP) (Chart 1) in aqueous solution was studied by pH-potentiometry, ^1H NMR spectroscopy and UV–vis spectrophotometry in order to determine the stoichiometry and stability of the complexes as well as the proton dissociation processes of the ligands.

2. Experimental

2.1. Chemicals

The ligands EHP and EHMP were prepared as described previously [18]. The purity and hydrolytic stability of the ligands was checked and the exact concentrations of the stock solutions were determined by the Gran method [27]. $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})\text{Cl}_2]_2$ was synthesized and purified according to a literature procedure [28]. A stock solution of $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})]$ was obtained by dissolving a known amount of $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})\text{Cl}_2]_2$ in water and the exact concentration was determined with pH-potentiometric titrations employing literature data for $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})]$ –hydroxido complexes [22].

2.2. pH-potentiometric measurements

The pH-potentiometric measurements for determination of the protonation constants of the ligands and the overall stability constants of the metal complexes were carried out at 25.0 ± 0.1 °C in water and at an ionic strength of 0.20 M (KCl, Sigma–Aldrich) in order to keep the activity coefficients constant. The titrations were performed with carbonate-free KOH solution of known concentration (0.20 M). Both the base and the HCl used were Sigma–Aldrich products and their concentrations were determined by pH-potentiometric titrations. An Orion 710A pH-meter equipped with a Metrohm combined electrode (type 6.0234.100) and a Metrohm 665 Dosimat burette were used for the pH-potentiometric measurements. The electrode system was calibrated to the $\text{pH} = -\log [\text{H}^+]$ scale by means of blank titrations (strong acid vs. strong base: HCl vs. KOH), as suggested by Irving et al.




Chart 1. Ligands used in this study: EHP = *N*-[(ethoxycarbonyl)methyl]-3-hydroxy-2-(1*H*)-pyridone; EHMP = *N*-[(ethoxycarbonyl)methyl]-3-hydroxy-4-methyl-2-(1*H*)-pyridone.

[29]. The average water ionization constant, pK_w , was determined as 13.76 ± 0.01 at 25.0 °C, $I = 0.20$ M (KCl), which corresponds well to the literature [30]. The reproducibility of the titration points included in the calculations was within 0.005 pH. The pH-potentiometric titrations were performed in the pH range 2.0–11.5. The initial volume of the samples was 10.0 mL. The ligand concentration was 2×10^{-3} M and metal ion-to-ligand ratios of 1:1 to 1:4 were used. The accepted fitting of the titration curves was always less than 10 μL . Samples were degassed by bubbling purified argon through them for ca. 10 min prior to the measurements and it was also passed over the solutions during the titrations.

For testing the hydrolytic stability of the ligands, stock solutions were prepared at various pH values (pH 1.83, 7.61 and 11.11) and titrations were performed at pH 1.83 after 0.5, 47 and 191 h, at pH 7.61 after 1, 48 and 120 h and at pH 11.11 after 0.17, 0.33, 1.42, 1.62, 2.7, 4, 24 and 188 h.

The protonation constants of the ligands were determined with the computer program HYPERQUAD [31]; PSEQUAD [32] was utilized to establish the stoichiometry of the complexes and to calculate the stability constants. β ($\text{M}_p\text{L}_q\text{H}_r$) is defined for the general equilibrium $p\text{M} + q\text{L} + r\text{H M}_p\text{L}_q\text{H}_r$ as $\beta(\text{M}_p\text{L}_q\text{H}_r) = [\text{M}_p\text{L}_q\text{H}_r] / [\text{M}]^p[\text{L}]^q[\text{H}]^r$ where M denotes a metal ion and L the completely deprotonated ligand. Literature $\log \beta$ values of the $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{hydroxido})]$ complexes were used [22] and compared to data collected in the course of the experiments described herein. In all calculations exclusively titration data were used from experiments in which no precipitate was visible in the reaction mixture.

2.3. UV–vis spectrophotometric and ^1H NMR measurements

A Hewlett Packard 8452A diode array spectrophotometer was used to record the UV–vis spectra in the interval 200–800 nm. The path length was 1 cm. Protonation and stability constants and the individual spectra of the species were calculated with the computer program PSEQUAD [32]. The spectrophotometric titrations were performed on samples of the ligands alone or with $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})]$ over the pH range 2.0–11.5 at an ionic strength of 0.20 M (KCl) and at 25.0 ± 0.2 °C. The concentration of ligands was set constant at 1×10^{-4} M and the metal-to-ligand ratios were 1:1 and 1:2.

^1H NMR studies were carried out on a Bruker Ultrashield 500 Plus instrument. 4,4-Dimethyl-4-silapentane-1-sulfonic acid was used as an NMR standard. The ligands were dissolved in a 10% (v/v) $\text{D}_2\text{O}/\text{H}_2\text{O}$ mixture to yield a concentration of 2–4 mM and were titrated at 25 °C, at $I = 0.20$ M (KCl) in absence or presence of $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})]$ at 1:1 and 1:2 metal-to-ligand ratios. ^1H NMR spectra were recorded to study the $\text{H}_2\text{O}/\text{Cl}^-$ exchange processes in the $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})]$ complexes at pH 5.8 and 7.4 in dependence of the Cl^- concentration (4–500 mM).

2.4. Determination of the distribution coefficient ($\log D_{7.4}$) of EHP and EHMP

$\log D_{7.4}$ values of EHP and EHMP were determined by the traditional shake flask method [33] in *n*-octanol/HEPES-buffered aqueous solution at pH 7.4 (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, HEPES) at 25.0 ± 0.2 °C. Two parallel experiments were performed for each sample. The ligands were dissolved at 0.10 mM in *n*-octanol pre-saturated aqueous solution of the buffer (10 mM) at constant ionic strength (0.20 M KCl). The aqueous solutions and *n*-octanol (1:1) were gently mixed with 360° vertical rotation for 2 h to avoid emulsion formation, and the mixtures were centrifuged at 5000 rpm for 3 min with a HeroLab centrifuge. After separation of the phases, UV spectra of the ligands in the aqueous phase were

compared with those of the original aqueous solutions in the range 250–400 nm and $\log D_{7.4}$ values were calculated using Equation (1).

$$\log D_{7.4} = \log \left(\frac{\text{Absorbance}_{\text{original solution}}}{\text{Absorbance}_{\text{aqueous phase}}} - 1 \right) \quad (1)$$

The absorbance was obtained at the region of λ_{max} (~ 300 nm) ± 10 nm. The partition coefficients ($\log P$) of **EHP** and **EHMP** were calculated using Equation (2).

$$\log P = \log \left(D \times \left(1 + \left(K_a / [H^+] \right) \right) \right) \quad (2)$$

3. Results and discussion

3.1. Proton dissociation processes and lipophilicity of the ligands

The proton dissociation processes of the ligands **EHP** and **EHMP** (Chart 1) in water were followed by pH-potentiometry, UV spectrophotometry and ^1H NMR titrations. The ligands contain ester functional groups and thus may undergo hydrolysis under acidic and basic conditions. Therefore, before studying the solution equilibria of the Ru complexes, a careful investigation of the hydrolytic stability of **EHP** and **EHMP** had to be performed. Stock solutions containing either ligand were prepared at pH 1.83, 7.61 and 11.11 and aliquots were titrated with the strong base KOH within a time frame of up to 191 h (Fig. S1). The formation of the carboxylic acid moiety by hydrolysis of the ester bond would result in extra base consumption and a shift of the equivalence point, which was only observed at pH 11.11. Within 3 h ca. 45% of the ester had hydrolyzed, and that remained constant during the rest of the experiment (Fig. S1.d). The hydrolytic stability of the ligands was also monitored by a second titration following re-acidification of the initially titrated aliquots of the acidic stock solution with the base. Overlapping consecutive titration curves were observed when the first titration was stopped at a maximum of pH ~ 10.4 , demonstrating that no measurable ester hydrolysis of **EHP** and **EHMP** takes place between pH 2 and 10.4. In addition, the hydrolysis of **EHP** was monitored at pH 7.4 by ^1H NMR spectroscopy (Fig. S2), which revealed that no measurable hydrolysis takes place at this pH value within 168 h. Based on these preliminary results, the proton dissociation constants (pK_a) of the ligands were calculated from data collected in the pH range 2.0–10.4. The pK_a values determined by the pH-potentiometric, UV and ^1H NMR titrations are collected in Table 1 and are in a fairly good agreement. The proton dissociation constants can be attributed to the deprotonation of the hydroxyl functional group. The pK_a of **EHP** was found to be somewhat lower than that of the structurally related 3-hydroxy-1-methylpyrid-2(1H)-one (MH2P, $pK_a = 8.89$ [34]) due to the electron-withdrawing effect of the ester moiety. The presence of the neighboring electron-donating methyl group adjacent to the hydroxyl in **EHMP** results in higher basicity compared to **EHP** and MH2P. The deprotonation of **EHP** and **EHMP** is accompanied by characteristic changes of the ligand bands in the UV spectra (for **EHP** see Fig. 1). The development of new strong bands at a higher λ_{max} value was observed for both ligands due to deprotonation which results in more extended conjugated π electron systems. The individual UV spectra of the ligand species (HL and L^-) were also calculated on basis of deconvolution of the pH-dependent spectra (Fig. S3 and Table 1). The constant location of the isosbestic points in the spectra of the ligands (see Fig. 1 for **EHP**) also indicates that the ester hydrolysis is negligible in the pH range studied (pH 2.0–10.4).

^1H NMR spectroscopic titrations of the ligands gave very similar results (see Fig. 2 for **EHP**, Fig. S4 for **EHMP**). The chemical shifts (δ)

Table 1

Proton dissociation constants (pK_a) of **EHP** and **EHMP** with λ_{max} , molar absorptivity ($M^{-1} \text{cm}^{-1}$) and calculated chemical shift (ppm) values for ligand species determined by UV spectrophotometric and ^1H NMR titrations ($T = 25.0$ °C, $I = 0.20$ M (KCl)).^a

	EHP		EHMP	
	HL	L^-	HL	L^-
pK_a (pH-potentiometry)	8.60(2)		9.20(3)	
pK_a (UV)	8.58(1)		9.21(1)	
pK_a (^1H NMR)	8.56(1)		9.19(1)	
Log $D_{7.4}$		-0.10(1)		+0.64(2)
Log P		-0.07		+0.65
λ_{max} (nm)/ ϵ ($\text{mol}^{-1} \text{dm}^3 \text{cm}^{-1}$)	300/6156 238/3227	314/7485 260/4935	298/6881 242/2616	312/8718 267/5427
δ /ppm ^b				
CH(4) (d)	7.179	6.767	–	–
CH ₃ (4) (s)	–	–	2.187	2.087
CH(5) ^c	6.440	6.313	7.112	6.725
CH(6) (d)	7.086	6.562	6.403	6.316
CH ₂ (q) ^d	4.264	4.250	4.256	4.242
CH ₃ (t) ^d	1.271	1.271	1.266	1.266

^a Uncertainties (SD) are shown in parentheses for the species characterized in the present work.

^b The signal of $-\text{CH}_2\text{C}=\text{O}$ (s) lies underneath the water peak.

^c CH(5) **EHP**: (d/d), **EHMP**: (d).

^d Data of ethanol for comparison: CH₂ (q) = 3.65 ppm; CH₃ (t) = 1.17 ppm.

of the aromatic CH protons are sensitive to the protonation state of the ligands, and upfield shifts of these protons of **EHP** by increasing pH are as shown in Fig. 3. Based on these changes, the pK_a values and chemical shifts of the individual ligand species (HL; L^-) were calculated (Table 1). Above pH 10, signals were assigned to the hydrolysis products, i.e. the corresponding 3-hydroxy-2-pyridone-1(2H)-carboxylate and ethanol (Fig. 2).

Furthermore, **EHP** and **EHMP** were also characterized with regard to their lipophilicity and distribution coefficients at physiological pH ($\log D_{7.4}$), as determined via *n*-octanol/water partitioning. The partition coefficients ($\log P$) of the neutral, non-ionized species were calculated from the $\log D_{7.4}$ values using the proton dissociation constants (Table 1). **EHMP** exhibits a more lipophilic character than **EHP** due to the additional methyl group.

3.2. Solution equilibria of $[\text{Ru}^{\text{II}}(\eta^6\text{-p-cymene})]$ complexes of **EHP** and **EHMP**

The complex formation processes of the ligands with $[\text{Ru}^{\text{II}}(\eta^6\text{-p-cymene})(\text{H}_2\text{O})_3]^{2+}$ were studied by pH-potentiometry, UV–vis spectrophotometry and ^1H NMR spectroscopy in aqueous solution. The stability constants of the minor and major dinuclear hydrolysis




Fig. 1. UV absorbance spectra of ligand **EHMP** recorded in the pH range of 2.0–10.3 ($c_{\text{EHMP}} = 0.1$ mM; $T = 25.0$ °C; $I = 0.20$ M (KCl)).




Fig. 2. Low (a) and high (b) field regions of the ^1H NMR spectra of EHP recorded at the indicated pH values ($c_{\text{EHP}} = 4 \text{ mM}$; $T = 25.0 \text{ }^\circ\text{C}$; $I = 0.20 \text{ M}$ (KCl); 10% D_2O). The peaks stemming from the hydrolysis products 3-hydroxy-2-pyridone-1(2H)-carboxylate (on a) and ethanol (on b) are annotated with stars.

products $[\text{Ru}_2(\eta^6\text{-}p\text{-cymene})_2(\text{OH})_2]^{2+}$ and $[\text{Ru}_2(\eta^6\text{-}p\text{-cymene})_2(\text{OH})_3]^+$, respectively, were determined by pH-potentiometry in the presence of 0.2 M KCl (Table 2) and were found to be in good agreement with data obtained by Buglyó and colleagues [22]. The chlorido ion is considered as a non-innocent ligand for Ru^{II} [15,19,35], and thus these stability data are regarded as conditional stability constants and are valid under the given conditions (0.2 M KCl, $T = 25 \text{ }^\circ\text{C}$). The aqueous solution behavior of $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})]$ can be described well with the formation of the above mentioned three kinds of species at 0.2 M KCl ionic strength [22,23]. However various chlorido, hydroxido and mixed chlorido–hydroxido complexes are present at acidic pH, rather than $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{H}_2\text{O})_3]^{2+}$ and $[\text{Ru}_2(\eta^6\text{-}p\text{-cymene})_2(\text{OH})_2]^{2+}$ [35]. Above pH ~ 6.5 the dinuclear complex $[\text{Ru}_2(\eta^6\text{-}p\text{-cymene})_2(\mu^2\text{-OH})_3]^+$ predominates [22,35]. It was also found that the hydrolytic equilibria are reached quickly so that pH-potentiometric titrations can be employed to follow the process.

The formation of the $\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})$ complexes with the ligands EHP and EHMP starts in the acidic pH range and the exclusive formation of mononuclear species with 1:1 metal-to-ligand ratio was identified. Stability constants of the complexes $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})]$ were determined by pH-potentiometry and UV–vis spectrophotometry monitoring complex formation *via* the changes of the charge transfer (CT) bands and they are in good agreement with each other (Table 2). In these complexes the bidentate (O,O) coordination mode of the ligands is the most feasible in solution, similarly to other hydroxypyridone compounds

[36] as demonstrated by single-crystal X-ray diffraction studies [18]. Due to the slow ligand exchange processes observed in the ^1H NMR spectra of the complexes with respect to the NMR time scale, the chemical shifts of the protons of the free and bound ligand and the $\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})$ moiety are clearly distinguishable (Figs. 4 and 5, Fig. S5).

The integrals of the pH-dependent proton peaks of the non-bound ligand and $\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})$ moiety and the peaks of the metal complexes are proportional to the molar fractions of the species (Fig. 6). The molar fractions of the bound and free metal ions were also calculated on basis of the determined stability constants. Very good correlation between the pH-potentiometric and ^1H NMR spectroscopic data were observed at $\text{pH} < ca. 6$. Up to this pH the formation of $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})]$ reaches a maximum and good quality ^1H NMR data was accessible (Fig. 4, Tables S1 and S2). The aromatic ring protons of the ligands and all the protons of the $\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})$ moiety show significant electronic shielding effects as compared with the HL ligand forms and ligand-free organometallic arene moiety.

The *mono*-ligand $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})]$ species, in which L is a bidentate ligand, often bear a chlorido leaving group, as also shown in the solid state by X-ray diffraction analysis [9,18,37,38]. These compounds can undergo aquation of the chlorido ligand in aqueous solution. This exchange process usually takes place fast and is considered to be an important step for the biological activation of the metal complex [15,17–19]. The extent of the aquation strongly depends on the type of the bidentate ligand and the actual chlorido concentration [15,17–19,35]. Therefore, the $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})(\text{H}_2\text{O})]^+ + \text{Cl}^- \rightleftharpoons [\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})(\text{Cl})] + \text{H}_2\text{O}$ equilibria were studied for the bidentate (O,O) donor ligands EHP and EHMP using ^1H NMR spectroscopy. Spectra were recorded at




Fig. 3. pH-dependence of the chemical shifts (δ) of the EHP protons: CH(4) (x); CH(6) (■); CH(5) (○) ($T = 25.0 \text{ }^\circ\text{C}$; $I = 0.20 \text{ M}$ (KCl); 10% D_2O).

Table 2

Overall stability constants ($\log \beta$) with some stepwise and derived constants of the $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})]$ complexes of EHP and EHMP ($T = 25.0 \text{ }^\circ\text{C}$, $I = 0.20 \text{ M}$ (KCl)).^a

	EHP	EHMP
$\log \beta$ ($[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})]$) (pH-metry)	8.49(1)	9.33(1)
$\log \beta$ ($[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})]$) (UV–vis)	8.55(9)	9.30(1)
$\text{p}K_{\text{a}}$ ($[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})]$) (^1H NMR) ^b	9.39(1)	9.46(3)
$\log K^{\text{c}}$ ($\text{H}_2\text{O}/\text{Cl}^-$) ^c	0.78(2)	0.96(2)
$\log K^{\text{d}}$	−0.11	+0.13

^a Uncertainties (SD) are shown in parentheses for the species characterized in the present work. Hydrolysis products of the metal ion: $\log \beta$ $[\text{Ru}_2(\eta^6\text{-}p\text{-cymene})_2\text{H}_2]^{2+} = -7.01(1)$ and $\log \beta$ $[\text{Ru}_2(\eta^6\text{-}p\text{-cymene})_2\text{H}_3]^+ = -11.99(1)$.

^b $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})] = [\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})(\text{OH})] + \text{H}^+$.

^c $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})(\text{H}_2\text{O})]^+ + \text{Cl}^- \rightleftharpoons [\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})(\text{Cl})] + \text{H}_2\text{O}$.

^d $\log K^{\text{e}} = \log \beta$ $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})] - \text{p}K_{\text{a}}(\text{HL})$.




Fig. 4. ^1H NMR spectrum of the $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})]\text{-EHP}$ system recorded at pH 6.09. The peaks with the gray background correspond to non-bound ligand and metal ion ($c_{\text{EHP}} = 2 \text{ mM}$; $\text{M:L} = 1:1$; $T = 25.0 \text{ }^\circ\text{C}$, $I = 0.20 \text{ M}$ (KCl), 10% D_2O).

pH 5.8 where the *mono*-ligand complexes predominate and at physiological pH (pH 7.4) using various chlorido concentrations (Fig. S6). Fast ligand exchange processes were observed in the ^1H NMR spectra as the signals of the aqua and chlorido species do not appear separately: A shift of the location of the cymene-CH peaks by about 0.1 ppm was observed by elevating the chlorido concentration. A similar tendency was seen at both pH values studied (Fig. 7). Based on these spectral changes the equilibrium constants

for the water/chlorido exchange reactions were estimated (Table 2). The calculations should be considered only as estimations since a high excess of chlorido ($\sim 0.5 \text{ M}$) was necessary to obtain saturation curves for the Ru complexes with a chlorido rather than an aqua ligand and thus the ionic strength of the solutions was not constant at 0.2 M. This effect was reached at a somewhat lower chlorido concentration in the case of **EHMP**, and consequently a slightly higher $\log K'$ value was obtained compared with **EHP**. According to these data about 38% and 55% of the **EHP** complex are chlorinated at 0.1 and 0.2 M chlorido concentration, respectively, while for **EHMP** approximately 48% and 65% of the chlorinated species were found.

^1H NMR titrations of the $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})]^{2+}$ -ligand systems clearly revealed various overlapping processes above pH 6 (Fig. 5). When elevating the pH value, the *mono*-ligand complex starts to dissociate resulting in the trihydroxido-bridged dinuclear species and the free ligand, which features a pH-dependent signal as its proton dissociation falls in this pH range. The dissociation of the $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})]$ species is relatively slow and could not be followed by pH-potentiometry as the real equilibria could not be reached during the time-scale of this method (*max.* $\sim 15 \text{ min}$ at each point). This is a possible reason why the fit between the molar fractions calculated based on pH-potentiometry and ^1H NMR spectroscopic data at $\text{pH} > 6.5$ is not satisfactory. In addition, the hydrolysis products of the ester bond cleavage of the ligand, *i.e.*, the carboxylate and ethanol are also formed in solution at $\text{pH} > \sim 9$ (Fig. 5). Ester hydrolysis of the complexes occurs only at a slightly lower pH than for the ligands. Thus, no strong catalytic effect on the ligand hydrolysis of the metal ion is probable. According to this finding, the coordination *via* the carboxylate side chain after hydrolysis of the ester moiety is also not likely to occur at $\text{pH} < 9$.




Fig. 5. Representative ^1H NMR spectra of the $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})]\text{-EHP}$ system recorded at various pH values ($c_{\text{EHP}} = 2 \text{ mM}$; $\text{M:L} = 1:1$; $T = 25.0 \text{ }^\circ\text{C}$, $I = 0.20 \text{ M}$ (KCl), 10% D_2O). The same symbols for peak assignments are used as in Fig. 4.




Fig. 6. Bound and ligand-free metal ion fractions for the $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})]\text{-EHP}$ (a) and -EHMP (b) systems calculated on the basis of the stability constants of the $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})]$ species (solid lines) and ^1H NMR peak integrals of the singlet CH_3 (cymene moiety) protons: bound (\bullet), free (\times) fractions. Errors are calculated with the help of the ligand distribution on basis of the ligand peaks in the NMR spectra ($c_{\text{ligand}} = 2 \text{ mM}$; $\text{M:L} = 1:1$; $T = 25.0 \text{ }^\circ\text{C}$, $I = 0.20 \text{ M}$ (KCl), $10\% \text{ D}_2\text{O}$).

The hydrolytic stability of the $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})]^{2+}\text{-EHP}$ ligand system was monitored at pH 7.40 by ^1H NMR spectroscopy for a week and only *ca.* 5% hydrolysis product was observed.

Besides the slow dissociation of the mono-ligand complex and the ester bond hydrolysis, a third process may be responsible for the significant shift of the ^1H NMR signals of the mono-ligand complex at $\text{pH} > 8$. Most probably the formation of a mixed hydroxido species $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})(\text{OH})]$ takes place. Due to the above mentioned slow complex dissociation processes, no reliable stability constant could be calculated for this complex based on pH-potentiometric experiments. However, pK_a values





Fig. 7. ^1H NMR chemical shifts (δ) of the $\text{CH}(6)$ and $\text{CH}(5)$ peaks of the $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})]^+$ complexes of **EHP** (black) and **EHMP** (gray), respectively, plotted against the chlorido concentration at pH 5.8 (\circ) and 7.4 (\times) together with the fitted curves ($c_{\text{ligand}} = 2 \text{ mM}$; $\text{M:L} = 1:1$; $T = 25.0 \text{ }^\circ\text{C}$, $10\% \text{ D}_2\text{O}$).

were estimated based on the pH-dependence of the signals of the $\text{CH}(\text{Ar})$ cymene protons in ^1H NMR spectra (Fig. S7, Table 2). The pK_a values of the *mono* complexes of **EHP** and **EHMP** are fairly similar and fall within the range found for half-sandwich Ru^{II} complexes with (O,O) coordinating ligands [9,14]. It is noteworthy that our data obtained in the presence of 0.2 M KCl are significantly higher as compared with the chloride-free medium [18], since the presence of competing chloride can suppress the hydrolysis of $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})]$.

3.3. Comparison of the stability of $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})]$ complexes of **EHP** with **EHMP** and other related ligands

Direct comparison of the stability constants of the $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})]$ complexes formed with the ligands **EHP** and **EHMP** (Table 2) reveals that the presence of the extra methyl group on the aromatic ring results in higher $\log \beta$ values, although the pK_a of **EHMP** is also higher. Therefore, the overall stability constants of the $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})]$ species were corrected by the different ligand basicities according to the following competition reaction:



$$\log K^* = \log \beta [\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})] - \text{pK}_a(\text{HL}) \quad (4)$$

A higher $\log K^*$ implies more favored metal complex formation as compared with the protonated ligand. Based on these derived constants ($\log K^*$ in Table 2), the electron donating methyl group adjacent to the coordination site in **EHMP** slightly increases the metal binding ability. The 3,4-hydroxypyridone deferiprone and maltol as a 3-hydroxy-4-pyrone feature similar structures as **EHP** and **EHMP** and the stability of their mono-ligand $\text{Ru}^{\text{II}}(\text{arene})$ complexes, which predominate at physiological pH in the mM concentration range are higher with $\log K^*$ values of 2.08 and 0.61 reported for deferiprone and maltol, respectively [23]. Consequently, the stability order of the (O,O) chelates is the following: **EHP** < **EHMP** < maltol < deferiprone. These results fit the generally accepted stability trend, *i.e.*, 3-hydroxypyrid-4-ones > 3-hydroxypyrid-2-ones [34]. According to these results, it can be concluded that **EHP** and **EHMP** possess moderate binding ability toward $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})]$ and significant dissociation of their complexes or the displacement of the original carrier ligand by other bioligands are probable under biologically relevant conditions, namely at low concentrations and at pH 7.4.

4. Conclusions

The two alkoxy carbonylmethyl-3-hydroxy-2(1H)-pyridones **EHP** and **EHMP** feature ethyl ester groups, which were found to be stable against hydrolysis in the pH range 2.0–10.4 in aqueous solution. The methylated derivative **EHMP** has higher basicity and lipophilicity. The stoichiometry and stability of their $\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})$ complexes were determined by pH-potentiometry, ^1H NMR spectroscopy and UV–vis spectrophotometry in aqueous solution. Formation of mono-ligand complexes was found with moderate stabilities in which the ligands coordinate in a bidentate fashion *via* their oxygen donors. These species predominate in the physiological pH range at mM concentrations, but considerable dissociation and the partial displacement of the original ligands by endogenous competitors is possible. In addition, chlorido/aqua co-ligand exchange processes for the $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})(\text{H}_2\text{O})]^+$ species were monitored. Based on these data, it can be estimated that in the complex up to 55–65% of the aqua ligand is replaced by

chlorido at 0.2 M chloride concentration. The ester groups of the ligands in $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})(\text{H}_2\text{O})]^+$ show considerable hydrolysis only in the basic pH range where significant dissociation of the complex and formation of dinuclear trihydroxido bridged $[\text{Ru}_2(\eta^6\text{-}p\text{-cymene})_2(\text{OH})_3]$ and the hydroxido species $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})(\text{L})(\text{OH})]$ was found.

Acknowledgments

This work has been supported by the Hungarian Research Foundation OTKA 103905, K77833 and É.A. Enyedy gratefully acknowledges the financial support of J. Bolyai research fellowship, C.G. Hartinger and Muhammad Hanif of the University of Vienna and the University of Auckland.

Appendix A. Supplementary data

Supplementary data related to this article can be found at <http://dx.doi.org/10.1016/j.jorganchem.2012.10.042>.

References

- [1] Y. Jung, S.J. Lippard, *Chem. Rev.* 107 (2007) 1387–1407.
- [2] L.R. Bernstein, in: M. Gielen, B.R.T. Tiekink (Eds.), *Metallotherapeutic Drugs and Metal-Based Diagnostic Agents: The Use of Metals in Medicine*, vol. 14, John Wiley & Sons, Ltd, 2005, pp. 259–277.
- [3] M. Galanski, V.B. Arion, M.A. Jakupec, B.K. Keppler, *Curr. Pharm. Des.* 9 (2003) 2078–2089.
- [4] P.J. Dyson, G. Sava, *Dalton Trans.* (2006) 1929–1933.
- [5] J.M. Rademaker-Lakhai, D. van den Bongard, D. Pluim, J.H. Beijnen, J.H. Schellens, *Clin. Cancer Res.* 10 (2004) 3717–3727.
- [6] E. Alessio, G. Mestroni, A. Bergamo, G. Sava, *Curr. Top. Med. Chem.* 4 (2004) 1525–1535.
- [7] C.G. Hartinger, M.A. Jakupec, S. Zorbas-Seifried, M. Groessl, A. Egger, W. Berger, H. Zorbas, P.J. Dyson, B.K. Keppler, *Chem. Biodivers.* 5 (2008) 2140–2155.
- [8] C.G. Hartinger, S. Zorbas-Seifried, M.A. Jakupec, B. Kynast, H. Zorbas, B.K. Keppler, *J. Inorg. Chem.* 100 (2006) 891–904.
- [9] W. Kandioller, A. Kurzwernhart, M. Hanif, S.M. Meier, H. Henke, B.K. Keppler, C.G. Hartinger, *J. Organomet. Chem.* 696 (2011) 999–1010.
- [10] W. Kandioller, C.G. Hartinger, A.A. Nazarov, C. Bartel, M. Skocic, M.A. Jakupec, V.B. Arion, B.K. Keppler, *Chem. Eur. J.* 15 (2009) 12283–12291.
- [11] J. Kljun, A.K. Bytzeck, W. Kandioller, C. Bartel, M.A. Jakupec, C.G. Hartinger, B.K. Keppler, I. Turel, *Organometallics* 30 (2011) 2506–2512.
- [12] N. Gligorijević, S. Arandelović, L. Filipović, K. Jakovljević, R. Janković, S. Grgurić-Sipka, I. Ivanović, S. Radulović, Ž.Lj. Tešić, J. Inorg. Biochem. 108 (2012) 53–61.
- [13] W.H. Ang, A. Casini, G. Sava, P.J. Dyson, *J. Organomet. Chem.* 696 (2011) 989–998.
- [14] A.M. Pizarro, M. Melchart, A. Habtemariam, L. Salassa, F.P.A. Fabbiani, S. Parsons, P.J. Sadler, *Inorg. Chem.* 49 (2010) 3310–3319.
- [15] F. Wang, H. Chen, S. Parsons, I.D.H. Oswald, J.E. Davidson, P.J. Sadler, *Chem. Eur. J.* 9 (2003) 5810–5820.
- [16] F. Beckford, J. Thessing, J. Woods, J. Didion, N. Gerasimchuk, A. Gonzalez-Sarrias, N.P. Seeram, *Metallomics* 3 (2011) 491–502.
- [17] M. Hanif, S.M. Meier, W. Kandioller, A. Bytzeck, M. Hejl, C.G. Hartinger, A.A. Nazarov, V.B. Arion, M.A. Jakupec, P.J. Dyson, B.K. Keppler, *J. Inorg. Biochem.* 105 (2011) 224–231.
- [18] M. Hanif, H. Henke, S.M. Meier, S. Martic, M. Labib, W. Kandioller, A. Jakupec, V.B. Arion, H.B. Kraatz, B.K. Keppler, C.G. Hartinger, *Inorg. Chem.* 49 (2010) 7953–7963.
- [19] M. Hanif, A.A. Nazarov, C.G. Hartinger, W. Kandioller, M.A. Jakupec, V.B. Arion, P.J. Dyson, B.K. Keppler, *Dalton Trans.* 39 (2010) 7345–7352.
- [20] A.F.A. Peacock, P.J. Sadler, *Chem. Asian J.* 3 (2008) 1890–1899.
- [21] C.G. Hartinger, P.J. Dyson, *Chem. Soc. Rev.* 38 (2009) 391–401.
- [22] P. Buglyó, E. Farkas, *Dalton Trans.* 38 (2009) 8063–8070.
- [23] L. Bíró, E. Farkas, P. Buglyó, *Dalton Trans.* 39 (2010) 10272–10278.
- [24] R. Fernandez, M. Melchart, A. Habtemariam, S. Parsons, P.J. Sadler, *Chem. Eur. J.* 10 (2004) 5173–5179.
- [25] W. Kandioller, C.G. Hartinger, A.A. Nazarov, M.L. Kuznetsov, R.O. John, C. Bartel, M.A. Jakupec, V.B. Arion, B.K. Keppler, *Organometallics* 28 (2009) 4249–4251.
- [26] E.A. Enyedy, E. Sija, T. Kiss, C.G. Hartinger, B.K. Keppler, T. Jakusch, unpublished data.
- [27] G. Gran, *Acta Chem. Scand.* 4 (1950) 559–577.
- [28] M.A. Bennett, T.N. Huang, T.W. Matheson, A.K. Smith, *Inorg. Synth.* 21 (1982) 74–78.
- [29] H.M. Irving, M.G. Miles, L.D. Pettit, *Anal. Chim. Acta* 38 (1967) 475–488.
- [30] SC Query, The IUPAC Stability Constants Database, Academic Software (Version 5.5), Royal Society of Chemistry, 1993–2005.
- [31] P. Gans, A. Sabatini, A. Vacca, *Talanta* 43 (1996) 1739–1753.
- [32] L. Zékány, I. Nagypál, in: D.L. Leggett (Ed.), *Computational Methods for the Determination of Stability Constants*, Plenum Press, New York, 1985, pp. 291–353.
- [33] S.K. Poole, C.F. Poole, *J. Chromatogr. B* 797 (2003) 3–19.
- [34] E.T. Clarke, A.E. Martell, *Inorg. Chim. Acta* 196 (1992) 185–194.
- [35] L. Bíró, E. Farkas, P. Buglyó, *Dalton Trans.* 41 (2012) 285–291.
- [36] L. Carter, D.L. Davies, J. Fawcett, D.R. Russel, *Polyhedron* 12 (1993) 1599–1602.
- [37] A.F.A. Peacock, M. Melchart, R.J. Deeth, A. Habtemariam, S. Parsons, P.J. Sadler, *Chem. Eur. J.* 13 (2007) 2601–2613.
- [38] A.J. Godó, A.Cs. Bényei, B. Duff, D.A. Egan, P. Buglyó, *RSC Adv.* 2 (2012) 1486–1495.